Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Citalopram withdrawal symptoms, also called discontinuation syndrome, usually begin within 2 to 4 days of stopping or lowering the dose and often ease within 1 to 3 weeks, though some people experience lingering effects for several weeks or months. Common symptoms include dizziness, flu-like fatigue, nausea, irritability, vivid dreams, anxiety, and "brain zaps," and their duration depends on how long you took the drug, your dose, how quickly you tapered, and your individual biology. There are several important factors and warning signs to consider, so see below to understand more about what shortens or prolongs recovery and when symptoms may signal returning depression rather than withdrawal.
Because withdrawal effects can closely mimic relapse, worsening mood disorders, or unrelated conditions, guessing on your own can delay the right care. A free, instant, online symptom check can help you organize what you are feeling, gauge urgency, and prepare clearer questions for your prescriber about tapering or next steps.
Last reviewed for medical accuracy: 09/24/2026
How Long Does Citalopram Withdrawal Last?
Citalopram is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for depression and anxiety. Though it is not classified as a controlled substance, it is a prescription‐only medication regulated by the FDA. Stopping citalopram too quickly can lead to withdrawal (also called discontinuation syndrome). Understanding what to expect can help you plan a safer taper and manage symptoms if they arise.
Over weeks or months of use, your brain adjusts to higher serotonin levels. Suddenly reducing or stopping citalopram forces your nervous system to rebalance. This shift can trigger a cluster of symptoms known as SSRI discontinuation syndrome.
Exact duration varies, but most people experience symptoms in three overlapping phases:
Early Onset (1–7 days)
Peak Phase (1–3 weeks)
Resolution or Protracted Phase (3 weeks–several months)
People can experience a mix of physical and emotional symptoms. Frequent complaints include:
Each person’s experience is unique. Key variables include:
A carefully planned taper is the gold standard for minimizing discontinuation symptoms. Strategies include:
Most withdrawal symptoms are uncomfortable rather than dangerous. However, reach out to a healthcare provider if you experience:
Before making changes to your medication, consider performing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Always speak to a doctor before stopping or changing your medication—and immediately if you experience anything that could be life-threatening or seriously impacts your wellbeing.
(References)
* Burke WJ. Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. doi: 10.1517/13543784.11.10.1477. PMID: 12387707.
* Ak S, Anıl Yağcıoğlu AE. Escitalopram-induced Parkinsonism. Gen Hosp Psychiatry. 2014 Jan-Feb;36(1):126.e1-2. doi: 10.1016/j.genhosppsych.2013.09.010. Epub 2013 Oct 5. PMID: 24176515.
* Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychother Psychosom. 2015;84(2):72-81. doi: 10.1159/000370338. Epub 2015 Feb 21. PMID: 25721705.
* Citalopram. 2006. PMID: 30000244.
* Chen A, Copeli F, Metzger E, Cloutier A, Osser DN. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia. Psychiatry Res. 2021 Jan;295:113641. doi: 10.1016/j.psychres.2020.113641. Epub 2020 Dec 13. PMID: 33340800.
* Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 5. PMID: 33549697.
* Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, Kendrick T, Kessler D, Mangin D, King M, Lanham P, Moore M, Nazareth I, Wiles N, Bacon F, Bird M, Brabyn S, Burns A, Clarke CS, Hunt A, Pervin J, Lewis G. Maintenance or Discontinuation of Antidepressants in Primary Care. N Engl J Med. 2021 Sep 30;385(14):1257-1267. doi: 10.1056/NEJMoa2106356. PMID: 34587384.
* Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. PMID: 36253442; PMCID: PMC9812779.
* Sharp T, Collins H. Mechanisms of SSRI Therapy and Discontinuation. Curr Top Behav Neurosci. 2024;66:21-47. doi: 10.1007/7854_2023_452. PMID: 37955823.
* Rissardo JP, Fornari Caprara AL, Bhal N, Repudi R, Zlatin L, Walker IM. Drug-Induced Myoclonus: A Systematic Review. Medicina (Kaunas). 2025 Jan 15;61(1). doi: 10.3390/medicina61010131. Epub 2025 Jan 15. PMID: 39859113; PMCID: PMC11767161.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.